skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Good morning,

Two questions this morning. Both are would you make the switch?

I have JNJ that I bought at the $65.00 range back in 2011I think. Would you sell and switch it to ABBV?? Or stay the course?

Same goes for PPL. I have owned it for quite a while and it has gone up nice. Would you switch it to IPL or stay the course?

Thanks
Jimmy
Read Answer Asked by Jimmy on February 22, 2019
Q: I am up on ABBV but think it is time to move on. What are your views on Stryker (SYK)? Any recommendations on other US Health stocks would be appreciated.
Read Answer Asked by Michael on February 06, 2019
Q: Hi,

I would like to get your opinion on the following healthcare and industrial stocks I am planning to buy in equal amounts. Would you recommend any other stocks for long term investments under my registered accounts.

Healthcare:- ABBV, MDT,PFE,GILD
Industrials:- HON,ITW, UTX

CELG is at a better value currently. Would you buy that instead of ABBV ?

Appreciate your service.

Thanks
Ninad
Read Answer Asked by Ninad on November 08, 2018
Q: Greetings team 5i,

Beside my core portfolio, I invest about 5% of my money in a “fun” portfolio. It has not been much fun recently. I bought ABBV (at the top) in order to write covered calls and cash-secured uncovered puts.

These calls, written just out-of-the-money and puts written just in-the-money on Mondays with the expiry date on the Friday of the same week, have produced premiums ranging from $US0.81 to $US2.73 which happened this week.

Why is there such a wide range of premium prices and what do the higher premiums suggest?

Thank you.

Milan
Read Answer Asked by Milan on October 30, 2018
Q: ABBV share price has slumped from approx. $95 to $82.50 in the past 5 days. Marinol was recently approved by the FDA. ABBV currently has a Forward P/E ratio of 10.72. I understand that the industry's average Forward P/E is 15.85.

What is your view of this stock. Seems like it might be an opportune time to buy and play the marijuana angle from a safe distance.

The Webinar yesterday was great. I hope there are more. Thank you for your services.
Read Answer Asked by Grant on October 26, 2018
Q: Hi Team, sold my shares of RHT this morning. Transferring remaining capital from sale to US RRSP for another healthcare name. Someone on T.V last night was screaming Medtronic for a buy ,from my own readings and research I see Stryker as a good choice. Between the 2 which has a better growth profile. Which would you choose. I own ABBV and BDX for a total healthcare exposure of 17%. I Thank-you in advance! Like usual,......Great work team! Sam
Read Answer Asked by sam on October 17, 2018
Q: Recently, 5i has supported members' suggestions to switch out of JNJ into something else given the legal difficulties that JNJ faces. I generally like to hold indefinitely; given this anticipated time frame, and my preference for safety and a good/growing dividend, do you think I should switch as well? Do you view the alternatives I've listed as less or more risky than JNJ overall? Are there non-pharmaceutical alternatives in the US healthcare space that would provide an equally secure and growing dividend that you would recommend? Thank you.
Read Answer Asked by Walter on August 08, 2018
Q: Hello, I am looking to add IHI to the healthcare allocation of my portfolio (10%) but would like to sell one existing holding first. Current healthcare related holdings are JNJ, ABBV, GUD and SIS (although I have SIS filed under Industrials). My question: which of JNJ and ABBV would you advise selling? Thank-you.
Read Answer Asked by Stephen on June 20, 2018
Q: What are you thoughts on buying these 2 stocks and can you recommend a good US divident paying ETF purchased with CAD - VUN ?
Read Answer Asked by Kim on March 26, 2018
Q: Thinking of this one in replacement of GILD that i sold 2 weeks ago. low p/e and peg, nice dividend but high debt.Argus and S&P by applying comp p/e come up with a target of 84$. Does it deserve the p/e or cheap for a reason?
What is your view on this one ?
Any suggestion ?
(like everybody else: I know you don't cover US stocks... bla bla bla)
Thanks much!
Read Answer Asked by Denis on March 03, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!